Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The following characteristics of the 'long-term responders' from the EAP; gender, ethnicity, smoking history (pack years), EGFR-TK mutation and histology of NSCLC. | Characteristics will be recorded once, retrospectively |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the long-term safety in subjects treated with gefitinib by collecting information on: All adverse events that have lead to an interruption/reduction of gefitinib or another intervention | Once, retrospectively for the period the patient has used gefitinib (minimal 3 years) | |
| long-term safety in subjects; what real life data measures are being taken by lung physicians to counter side effects caused by long term gefitinib treatment; the number, reason, effect and description of interventions that have been taken |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients from the gefitinib Expanded Access Programme in the Netherlands.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Amsterdam | Netherlands | ||||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Once, retrospectively for the period the patient has used gefitinib (minimal 3 years) |
| long-term safety: Number, reason and effect of interruptions during gefitinib use to determine side effects typical for the long-term treatment with gefitinib | Once, retrospectively for the period the patient has used gefitinib (minimal 3 years) |
| Apeldoorn |
| Netherlands |
| Research Site | Groningen | Netherlands |
| Research Site | Helmond | Netherlands |
| Research Site | Hengelo | Netherlands |
| Research Site | Hoofddorp | Netherlands |
| Research Site | Leiden | Netherlands |
| Research Site | The Hague | Netherlands |
| Research Site | Veldhoven | Netherlands |
| Research Site | Venlo | Netherlands |
| Research Site | Zutphen | Netherlands |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |